Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (555)	12/14/2004 10:12:24 AM
From: richardred	Read Replies (1) \| Respond to of 7265

BMY looks to be hunting to. >Bristol-Myers Squibb to focus on its strategic priorities in developing its pipeline and new product opportunities Bristol-Myers Squibb to Sell Oncology Therapeutics Network Tuesday December 14, 9:23 am ET NEW YORK, Dec. 14 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY - News) has signed a definitive agreement to sell its Oncology Therapeutics Network (OTN) unit to One Equity Partners LLC. It is expected that this transaction will be completed during the first quarter of 2005, pending certain regulatory approvals. biz.yahoo.com The divestiture of OTN will further enable Bristol-Myers Squibb to focus on its strategic priorities in developing its pipeline and new product opportunities in ten disease areas of significant unmet medical need. OTN is a leading specialty distributor of pharmaceuticals to office-based oncologists. For the year ended December 31, 2003, OTN generated revenues of $2.2 billion and earnings before minority interest and income taxes of $14 million. Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.